Third, the severe murine AKI models (40-min I/R, CLP) may not reflect epigenetic landscapes in milder clinical cases, and the specificity of pharmacological inhibitors (e.g., C646) for P300/Cbp is uncertain due to potential off-target effects on other histone acetyltransferases. This evidence concerns the gene CREBBP and acute kidney injury.